n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 13th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Inspyr Therapeutics, Inc. (NSPX)

Zacks and BUYINS.NET reported earlier on Inspyr Therapeutics, Inc. (NSPX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients with numerous different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTC Markets Group’s OTCQB. 

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. 

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer. 

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program focuses on the treatment of gastric cancer.

Inspyr has commenced a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.  

In addition, the Company plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer.

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.      
  
In May 2017, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company.

In October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary compounds generated via the Company’s adenosine receptor modulator (ARM) technology platform. The preclinical study will assess adenosine receptor agonists for the management of atherosclerosis.

Furthermore, in October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics has fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia. At these laboratories, a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.

Inspyr Therapeutics, Inc. (NSPX), closed Wednesday's trading session at $0.05, up 9.89%, on 30,017 volume with 6 trades. The average volume for the last 60 days is 32,871 and the stock's 52-week low/high is $0.0305/$1.26.

FieldPoint Petroleum Corp. (FPPP)

Stock Twits, InvestorsHub, TMX Money, OTC Markets, Equity Clock, MarketWatch, and The Street reported on FieldPoint Petroleum Corp. (FPPP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FieldPoint Petroleum Corp. engages in the acquisition, development, and operation of oil and natural gas properties in the U.S. The Company engages in oil and natural gas exploration, production and acquisition, mainly in Louisiana, New Mexico, Oklahoma, Texas, and Wyoming.

On November 29, 2017, FieldPoint Petroleum was approved for quotation on the OTC.QB and OTC.PINK. Formed in 1989, the Company is headquartered in Austin, Texas.

FieldPoint Petroleum’s corporate strategy concentrates on expanding its reserve base. This is while growing production and cash flow via the acquisition of leasehold interests and producing oil and gas wells. At present, FieldPoint Petroleum has varying ownership interests in 480 gross producing wells (96 net) in the above-mentioned States.

However, more recently, the Company has selected to center on promising regions for oil & gas exploration. This includes the Lusk Field in Lea County, New Mexico, and FieldPoint’s Ranger Project in the Taylor Serbin Field near Giddings, Texas. In projects like these, the Company partners with enterprises that complement internal expertise in assessing opportunities and in making investment decisions.

Pertaining to producing oil & gas properties, the Company operates 19 wells. Independent contractors operate the other wells per standard industry contracts.

Regarding operated wells, FieldPoint Petroleum’s portfolio includes primarily low-touch, “pumper and electricity-only” wells in the Devonian, Ellenberger, and Morrow regions of West Texas and New Mexico.

Higher maintenance fields are closer to home, including the Taylor Serbin field close to Giddings, Texas. Most of FieldPoint Petroleum’s production comes from its East Lusk and Serbin Fields.

In Texas, FieldPoint Petroleum is active in Andrews County, Midland County, and Lee & Bastrop Counties. In Oklahoma, it is active in Grady County and Pontotoc County. In Louisiana, the Company is active in Caddo Parrish.

Furthermore, FieldPoint Petroleum is active in Lea County, Chaves County, and Eddy County in New Mexico. In Wyoming, FieldPoint is active in Converse County and Campbell County.

FieldPoint Petroleum Corp. (FPPP), closed Wednesday's trading session at $0.18, up 13.92%, on 17,108 volume with 14 trades. The average volume for the last 60 days is 6,415 and the stock's 52-week low/high is $0.10/$0.20.

Elcora Advanced Materials Corp. (ECORF)

InvestorIntel reported previously on Elcora Advanced Materials Corp. (ECORF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Elcora Advanced Materials Corp. has been designed to become a vertically integrated (from mine to product) graphite & graphene company, which mines, processes, refines graphite, and produces the graphene and end user graphene applications. The Company has developed a unique low cost-effective process to make high quality graphite and graphene that are commercially scalable. Elcora Advanced Materials is based in Bedford, Nova Scotia. The Company lists on the OTC Markets’ OTCQB.

Elcora Advanced Materials is targeting high-end graphite applications (Li-ion batteries, graphene production & coating). It acquired the full operational control and a 40 percent equity interest in Sakura Graphite (PVT) Limited, operators of the Ragedara mine in Sri Lanka. Sri Lanka graphite is very high quality with many unique properties. This graphite is suitable for use in numerous high-end graphite applications.

Elcora has secured high-grade graphite and graphene precursor graphite from its interest in the operation of the Ragedara mine in Sri Lanka. This mine is already in production. Currently, the mine yields about 500 tonnes each year.

The Company developed its own unique graphite refining process. The process does not require the use of acids or alkaline systems. Environmentally friendly, the process yields higher quality graphite that has not been oxidized and will withstand high temperatures.

Elcora announced in April 2017 that it is building a state-of-the-art Lithium Ion (Li-ion) battery research and development laboratory in Halifax, Nova Scotia. The lab will concentrate on quality control and developing the Company’s graphite anode powder for Li-ion batteries.

Graphite powder will be routinely tested employing industry standard cells. This is to ensure the coulombic efficiency, reversible capacity, first-cycle loss and rate capabilities of the product are within Elcora’s specifications.

Last month, Elcora Advanced Materials announced that it is working with a number of battery manufacturers in Asia that are testing the Company’s graphite anode powder. Elcora has so far sent more than14 kgs of its EL-I-C6 graphite anode powder to battery manufacturers to test its electrochemical performance.

The purpose of this testing is to demonstrate that the Company’s EL-I-C6 graphite anode powder meets Li-ion battery manufacturing standards. After more testing, Elcora Advanced Materials hopes to enter into negotiations for long-term supply agreements.

Moreover, in November, Elcora announced it signed a Memorandum of Understanding (MOU) agreement with Lockheed Martin Canada. This represents Lockheed Martin's first battery technology investment in Canada.

The strategic partnership supports the increasing energy demand for Lithium-Ion battery storage solutions applied to commercial, industrial, utility, and military applications. The MOU formally creates a working relationship and guidelines to support/identify opportunities within Lockheed Martin business units; including Lockheed’s energy division to help in maximizing and attaining sales goals.

Elcora Advanced Materials Corp. (ECORF), closed Wednesday's trading session at $0.3442, up 12.08%, on 3,255 volume with 5 trades. The average volume for the last 60 days is 42,350 and the stock's 52-week low/high is $0.117/$0.439.

Abattis Bioceuticals Corp. (ATTBF)

Stockgoodies, Cannabis Financial Network News, Greenbackers, PennyStocks24, Promotion Stock Secrets, InvestorIntel, CFN Media Group, Goldman Small Cap Research, and Information Solutions Group reported previously on Abattis Bioceuticals Corp. (ATTBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abattis Bioceuticals Corp. is a specialty, vertically-integrated biotechnology enterprise. The Company aggregates, incubates, integrates, and invests in the botanical drug development industry. Its divisions include Biocell Labs, Inc. and Vergence Sales & Marketing, Inc. By way of these, Abattis develops and licenses natural health products. The Company’s other divisions are Northern Vine Canada, Inc.; North American Bioextracts, Inc.; and Biocube Green Grow Systems Corp. OTCQB-listed, Abattis Bioceuticals is based in Vancouver, British Columbia.

The Company’s products and services include Botanical Blends & Formulas; CBD Ingredients; Functional Foods & Beverages; Research and Development (R&D); Analytical Services; and Pharma & Nutraceuticals. Abattis has received a Natural Product Number (NPN) approval for Phyto (NOS). This NPN allows it to manufacture and sell Phyto (NOS) in Canada.

Phyto (NOS) has applications in a wide spectrum of food, beverage, and nutraceutical products. Phyto (NOS) is an all-natural, patent-pending formulation. It naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants.

Abattis Bioceuticals has capabilities that support the production and extraction of botanical ingredients for its products; one of which includes cannabis. The Company develops and licenses natural health products, medicines, extractions, and ingredients - some of which will contain cannabinoid compounds. In addition, Abattis has an extensive pipeline of high-quality products and intellectual property (IP) for the fast-developing botanical drug market.

Abattis Bioceuticals and Northern Vine entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100 percent of Experion Biotechnologies, Inc. Abattis Management has been concentrating their efforts on its Northern Vine Lab buildout after receiving their controlled substance dealers license (CSL) in 2016. Northern Vine Labs has the required licenses and controls in place to legally possess and work with the raw herb (cannabis) and its active ingredients.

Recently, Abattis Bioceuticals announced it reached a definitive agreement with Global Damon Pharma (GD Pharma) of South Korea. This agreement is to distribute and sell Abattis’ product lines exclusively in South Korea. The agreement permits GD Pharma to commence sales of Abattis products in South Korea effective immediately. Abattis Bioceuticals and GD Pharma plan to work together on new formulations via Abattis’ subsidiary Northern Vine Canada.

In November, Abattis Bioceuticals announced the closing of its agreement with Emerald Health Therapeutics, Inc. Emerald has invested $2.5 million into Northern Vine Canada in exchange for a 53 percent equity stake in Northern Vine. Northern Vine has now received the $2.5 million investment. Abattis Bioceuticals remains a 47 percent equity stakeholder in Northern Vine.

Yesterday, Abattis Bioceuticals announced the successful completion of experiments confirming column chromatography extraction technology. These experiments measured the feasibility of applying the technology for the extraction of CBD, THC and THCA from industrial hemp and cannabis. Throughputs, yields, purity, as well as terpene profiles were also part of the range of work performed at its facility, Northern Vine Labs.

Abattis Bioceuticals Corp. (ATTBF), closed Wednesday's trading session at $0.47, up 10.59%, on 10,305,898 volume with 3,172 trades. The average volume for the last 60 days is 1,007,917 and the stock's 52-week low/high is $0.0471/$0.5793.

Premier Holding Corp. (PRHL)

OTC Markets, InvestorsHub, Street Insider, Stockhouse, Investors Hangout, and StockFlare reported on Premier Holding Corp. (PRHL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Premier Holding Corp., by way of its subsidiaries, provides energy efficiency products and services. It does so mainly to commercial middle market companies and residential customers in the U.S. Premier provides financial support and management expertise. This includes access to capital, financing, legal, insurance, mergers, acquisitions, joint ventures (JVs) and management strategies. Listed on the OTCQB, Premier Holding has its corporate office in Tustin, California.

Premier Holding’s companies have wide-ranging experience in technologies and services for deregulated power and expertise in energy reduction. Fundamentally, its companies lower its clients’ price and usage of energy. Premier's mission is to acquire clean technology companies and/or green products and services, which are accretive and that can be seamlessly integrated and use the overall economics of such products and services for the benefit of its customers.

The Company’s holdings include The Power Company and E3 - Energy Efficiency Experts. The Power Company is an experienced energy consulting firm in the deregulation space. It uses its market standing and its large, well-established network of energy suppliers to compete for its clients’ business. The Power Company serves as its clients’ energy advocates. Moreover, it negotiates the most competitive pricing and options for its clients.

The Power Company received the "2017 Leaders Diamond" Award from a major deregulated power supplier. The award combines the volume of sales, connected with the sales of home products. It calculates this with a quality score by customers to create a "Sales Quality" Score. The team at TPC attained the highest score among all resellers for 2017.

E3 - Energy Efficiency Experts is an Energy Services Company (ESCO). E3 was created by Premier Holding to provide the best-of-breed energy reduction solutions for its customers. E3 works to provide the most current, fully-vetted solutions in energy reduction technologies. It also works to provide management tools that capture the client for future opportunities.

Today, Premier Holding announced that its subsidiary, The Power Company (TPC), supports another large commercial contract. This indicates its breadth of sales into the residential and commercial sectors. TPC continues to help manage and lessen the energy costs for one of the largest and fastest growing physical therapy companies in the nation.

Recently, TPC secured the energy supply for its customer's newest properties in Texas. This helps to manage an important business expense for its customer, while the company continues to expand through organic growth and acquisitions. In addition, this company is in talks to further help reduce its customer's energy costs through the implementation of LED lighting for its locations throughout the country via Premier’s energy efficiency division, E3 - Energy Efficiency Experts.

Premier Holding Corp. (PRHL), closed Wednesday's trading session at $0.031864, up 10.64%, on 70,252 volume with 9 trades. The average volume for the last 60 days is 68,651 and the stock's 52-week low/high is $0.0221/$0.089.

Zenergy Brands, Inc. (ZNGY)

OTC Markets, MarketWatch, InvestorsHub, Barchart, Stockhouse, GuruFocus, Investopedia, and Stockopedia reported on Zenergy Brands, Inc. (ZNGY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Zenergy Brands, Inc. is a next-generation energy and technology business. The Company operates in the developing smart energy, conservation, and utility industries. The Company was previously known as The Chron Organization, Inc. Zenergy Brands lists on the OTC Markets Group’s OTCQB. The Company has its headquarters in Dallas, Texas.

On December 4, 2017, Zenergy Brands announced that effective on that date, FINRA (Financial Industry Regulatory Authority, Inc.) approved the Company’s name change from The Chron Organization, Inc to Zenergy Brands, Inc. In addition, FINRA approved Zenergy Brands’ ticker symbol change to ZNGY.

The Company’s vision is to enrich businesses via responsible energy use and management. Zenergy is working to considerably lessen the carbon footprint in the United States. It is also working to substantially decrease the demand on the nations’ national energy grid and on the nation’s water supply.

Zenergy Brands’ Chief Executive Officer, Mr. Alex Rodriguez, said earlier this month, “We are thrilled that this name and associated ticker symbol change is now official. The name Zenergy, which we have also successfully registered as a trademark with the US Patent and Trademark Office, effectively denotes the essence of our refined vision and direction. Secondly, I strongly believe that the brand perfectly captures the convergence of the utilities and the smart controls industries, which is exactly what our Company encompasses.”

Zenergy Brands specializes in decreasing utility expenses (electricity, natural gas, and water) by 20 percent to as much as 60 percent in certain cases by way of its innovative Zero Cost Program. Zenergy provides energy conservation, smart controls, and efficiency-based products and services to commercial, industrial, and municipal end-use customers.

Today, Zenergy Brands announced a complete family of social media channels for its business operations and also a new corporate website, ZenergyBrands.com, and a customer-facing website, whatiszenergy.com. Zenergy Brands has completely rebranded its entire online presence under its new trademark name, Zenergy™.

Zenergy Brands, Inc. (ZNGY), closed Wednesday's trading session at $0.0129, up 29.00%, on 559,200 volume with 25 trades. The average volume for the last 60 days is 125,465 and the stock's 52-week low/high is $0.0055/$0.048.

PEN, Inc. (PENC)

DreamTeamNetwork, Outcast Traders, and SmallCapVoice reported earlier on PEN, Inc. (PENC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, PEN, Inc. is an international leader in developing, commercializing, and marketing enhanced-performance products enabled by nanotechnology. PEN stands for Products Enabled by Nanotechnology. Products from its family of companies are for healthcare to homecare, homeland defense to food security, and transportation to recreation. PEN has its head office in Miami, Florida.

PEN is the combination of Nanofilm, Ltd. and Applied Nanotech Holdings, Inc. These are two nanotechnology innovators. PEN formed to channel the potential of nanotechnology in real-world products for real-world users. With the combination of these two companies, PEN provides nano-layer coatings, nano-based cleaners, as well as nano-composite products.

PEN’s Applied Nanotech, Inc. subsidiary is based in Austin, Texas. It functions as the Design Center conducting contract services for government and private customers and new product development for PEN centering on inventive and advanced product solutions in the areas of safety, health, and sustainability.

Applied Nanotech Holdings (the PEN Design Center) has over 25 years in the industry. It holds in excess of 250 patents. It has partnered with organizations like the U.S. Department of Transportation, the Army Research Office, and the U.S. Department of Agriculture to find nanotechnology-based solutions to challenges.

PEN, via its wholly-owned subsidiary PEN Brands LLC (formerly Nanofilm Ltd.), develops, manufactures, and sells products based on nanotechnology. This includes its Ultra Clarity® brand eyeglass cleaner, CLARITY DEFOG IT™ brand defogging products, CLARITY ULTRASEAL® nanocoating products for glass and ceramics, and an environmentally friendly surface protector, fortifier, and cleaner.

Last month, PEN reported financial results for its Q3 ended September 30, 2017. For the quarter, total revenues were $2,028,261, versus revenues of $2,006,838 in the comparable period in 2016.

For Q3 of 2017, overall gross profit amounted to $632,982 versus $631,083 for the Q3 of 2016. Gross margin was 31 percent. This was relatively unchanged from the prior year period.

Operating loss was $48,131 in Q3 of 2017, versus an operating loss of $235,772 in Q3 of 2016. Net loss for the three months ended September 30, 2017 was $124,730 or ($0.04) per basic and diluted share, versus a net loss of $210,902, or ($0.07) per basic and diluted share, for the three months ended September 30, 2016.

PEN, Inc. (PENC), closed Wednesday's trading session at $1.45, up 19.83%, on 292 volume with 2 trades. The average volume for the last 60 days is 2,533 and the stock's 52-week low/high is $0.71/$1.90.

graphic

The QualityStocks
Company Corner

graphic
graphic

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.1209, up 14.88%, on 23,321,214 volume with 1,670 trades. The stock’s average daily volume over the past 60 days is 8,270,895, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) is pleased to announce that it has executed a Letter of Intent with SinglePoint, Inc., (“SinglePoint) (OTC:SING) a full service mobile technology provider whom Global intends to begin collaborating with to maximize its existing suite of financial technology solutions, including those utilized by its majority owned subsidiary, MoneyTrac Technology, Inc.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. Looks to Optimize Financial Payment Platforms Through Partnership with SinglePoint, Inc.

CannabisNewsWire Announces Publication on Various Applications of Blockchain Technology

MoneyTrac Technology, Inc. Secures Revenue Opportunity with Definitive Referral and Consultant Partnership Agreement with GreenRush Group, Inc.

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.886, up 2.07%, on 193,746 volume with 148 trades. The stock’s average daily volume over the past 60 days is 137,508 and its 52-week low/high is $0.2864/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to announce it has signed a definitive agreement with 8230137 Canada Inc. and the minority shareholders of ZincNyx Energy Solutions, Inc. to acquire all the issued and outstanding shares of ZincNyx. Upon closing of the Agreement ZincNyx will become a 100% owned subsidiary of the Company.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals to Acquire Zinc Air Battery Developer ZincNyx Energy Solutions

MGX Minerals Closes $6.3 Million First Tranche of Non-Brokered Private Placement

MGX Minerals and PurLucid Treatment Solutions Announce Initial Commissioning of Rapid Lithium Recovery System, Deployment Site and Water Processing Contract

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (FTSSF). Today, Petroteq Energy Inc. closed trading at $1.75, up 1.92%, on 27,021 volume with 65 trades. The stock’s average daily volume over the past 60 days is 80,846, and its 52-week low/high is $0.015/$1.8892.

PetroBLOQ, LLC, a collaboration formed by Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF) with First Bitcoin Capital Corp, (TSX VENTURE: PQE; OTCQX: PQEFF; FRANKFURT: A2DYWC) announces that it has appointed Joseph Abrams to its Board of Advisors.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Announces Appointment of Joseph Abrams to Board of Advisors of PetroBLOQ

Petroteq Energy Announces Membership in American Petroleum Institute

Petroteq Energy Announces Petrobloq's Membership in Enterprise Ethereum Alliance

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.75647, up 0.30%, on 1,276,215 volume with 740 trades. The stock’s average daily volume over the past 60 days is 903,039, and its 52-week low/high is $0.101/$0.8611.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. The publication, titled “The Therapeutic Potential of Pharmacologically Active Cannabinoids,” reviews the market for cannabinoid therapies and InMed’s proprietary biosynthesis process to manufacture pharmaceutical-grade (greater than 95% purity) cannabinoids using a cost-effective, laboratory-based process. To view the full publication, visit: https://www.networknewswire.com/therapeutic-potential-pharmacologically-active-cannabinoids/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential

The Therapeutic Potential of Pharmacologically Active Cannabinoids

Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.749, off by 0.13%, on 268,116 volume with 117 trades. The stock’s average daily volume over the past 60 days is 148,244 and its 52-week low/high is $0.40/$2.75.

ChineseInvestors.com (CIIX) today announces plans to spin off its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc., to be registered as a separate publically traded company allowing CIIX to focus on its new Cryptocurrency Division and its Core Financial Education Business. The Company's Board of Directors approved plans to spin off the Consumer Products Division in both the United States and China, which includes its hemp oil assets and its new wholesale alcohol distribution business, at the end of February 2018.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc. Announces its Plan to Spin Off its Wholly-owned Foreign Entity, CBD Biotechnology Co. Ltd., and its Wholly-owned Subsidiary, ChineseHempOil.com, Inc. to Allow the Company to Focus on its New Cryptocurrency Division and its Core Financial Education Business

ChineseInvestors.com, Inc. Announces That it has Entered Into an Agreement With Blockchain BT, LLC to Host a Bitcoin ATM at its San Gabriel, California Office With Plans to Expand to Serve Other Chinese Communities Throughout the United States

ChineseInvestors.com, Inc. (CIIX) OptHemp Line Achieves a Big Hit with Product Launch

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.65, off by 13.61%, on 1,547,491 volume with 1,311 trades. The stock’s average daily volume over the past 60 days is 322,717 and its 52-week low/high is $0.1999/$2.13.

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) a drug delivery platform innovator, announces the United States Patent and Trademark Office has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications; and nicotine.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

NetworkNewsWire Announces Publication on M&A Action in the Cannabis Industry

Merger and Acquisition Activity is Heating Up in the Cannabis Industry

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0649, up 0.15%, on 10,951,206 volume with 546 trades. The stock’s average daily volume over the past 60 days is 3,323,204, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc. (OTC Pink: POTN) announces today that the Company has been recently featured in a Huffington Post article highlighting the bolstering emergence of the CBD industry. The article stated: “In the past 5 years, the legal status of cannabis has continued to evolve in the U.S. Over 22 states including the District of Columbia have authorized the medical and recreational use of cannabis. In fact, the North America Cannabis market is poised to be worth $20 billion by 2020.”

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding Acclaimed as One of Five Notable CBD Revolution Industry Leaders on Huffington Post

PotNetwork Holding, Inc. PCOAB Concludes Initial Auditing Requirement for Up-List

PotNetwork Holding, Inc. to Retire over 52% of Issued and Outstanding Common Shares

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

MarketBeat
(CPAH) +62.79%

2.

Wolf of Penny Stocks
(PSID) +50.00%

3.

QualityStocks
(ZNGY) +29.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251